New AREDS2 + B-Vitamin Research: What the Latest Study Means for Your Eyes (2026)

Written by Dr. Louis Michaelos, Ophthalmologist & Founder, MacuRest | Last reviewed July 2026

TL;DR: At the American Optometric Association's 2026 meeting, Bausch + Lomb researchers presented new preclinical data testing whether adding a B-vitamin complex to the AREDS2 formula improves protection against AMD at the cellular level. The study used donor retinal cells carrying high-risk AMD genes. It's early-stage lab research, not a completed clinical trial — but it adds real scientific backing to the B-vitamin approach that both PreserVision AREDS3 and MacuRest already use, alongside MacuRest's addition of melatonin.

What the New Study Actually Tested

In June 2026, Dr. Lori-Ann Christie, senior director of Biological Research at Bausch + Lomb, presented a poster titled “Comparative Analysis of AREDS2 and AREDS2+B Vitamin Complex in an in vitro Model of Age-Related Macular Degeneration” at the AOA's Optometry's Meeting in Phoenix. Her team's preclinical study, conducted ahead of the PreserVision AREDS3 launch, used human retinal pigment epithelial (RPE) cells — the tissue layer at the back of the eye most affected by AMD — taken from a donor carrying high-risk AMD genetic markers (CFH, ARMS2, and HTRA1).

The goal was to see, at the cellular level, whether adding a B-vitamin complex to the standard AREDS2 formula changes how these at-risk cells respond, compared to AREDS2 nutrients alone.

Why This Kind of Study Matters (and Its Limits)

It's worth being precise about what this is: a laboratory study on donor cells, not a clinical trial in patients. That distinction matters. The original AREDS2 trial that shaped current treatment guidelines followed over 4,000 real patients for five years. In vitro cell studies like this one are an earlier step — they help explain a possible biological mechanism and justify further research, but they don't by themselves prove that a B-vitamin complex slows AMD progression in people.

That said, this kind of mechanistic research is exactly how new formulations get scientific grounding before larger studies are designed. It's a reasonable first data point behind the B-vitamin additions that have started showing up in AREDS2-based products.

How This Connects to the AREDS2 vs AREDS3 Conversation

This research lands directly on a question a lot of patients have been asking since PreserVision launched its AREDS3 Formula Soft Gels earlier this year: do the added B-vitamins actually do anything? Until now, the honest answer was that B-vitamins were included based on general nutritional science, not AMD-specific trial data. This new preclinical work is one of the first pieces of AMD-specific cellular evidence looking at that exact question.

MacuRest was formulated with a B-complex for similar reasons, arrived at independently — and went a step further by adding melatonin, which neither PreserVision formula includes. For the full formula-by-formula comparison, see our AREDS2 vs AREDS3 breakdown.

The Bigger Picture: AMD Research Keeps Moving

This study is part of a broader wave of AMD research this year. A separate reanalysis of the original AREDS and AREDS2 trial data, published by the National Eye Institute, found that the AREDS nutrient combination slowed the expansion of geographic atrophy — the advanced, vision-threatening form of dry AMD — by roughly half over a three-year period in patients whose lesions started away from the central retina. Alongside newer investigational approaches like gene therapy and retinal implants for advanced disease, it's a reminder that nutritional support remains a foundational, well-evidenced piece of AMD management even as other treatment options develop.

The MacuRest Difference

MacuRest combines the proven AREDS2 nutrients with a B-vitamin complex and 5mg of melatonin, formulated for evening use. The retinal pigment epithelium does its most important repair work overnight, and AMD patients tend to have lower melatonin levels than people without the disease — a 2024 study in JAMA Ophthalmology linked melatonin use to significantly lower AMD progression rates across more than 100,000 patients.

MacuRest also uses 25mg of zinc rather than the 80mg found in PreserVision's formulas, chosen for better day-to-day tolerability. GI discomfort from high-dose zinc is one of the most common reasons patients stop taking their supplement altogether — and a supplement taken consistently every night matters more than one taken at a higher dose inconsistently.

See the MacuRest formula → | AREDS2 vs AREDS3 full comparison | Best time to take AREDS2

Frequently Asked Questions

Is the new B-vitamin research a clinical trial?

No. It's a preclinical, in vitro study using donor retinal cells with high-risk AMD genetic markers, presented as a poster at the AOA's 2026 meeting. It's an early step that can help justify future clinical research, not proof of benefit in patients.

Does this mean I should switch to a B-vitamin AREDS2 supplement?

Not necessarily. The AAO-recommended standard for intermediate-to-advanced AMD remains the original AREDS2 formula. This research adds supporting evidence for the B-vitamin approach used in some newer formulas, including PreserVision AREDS3 and MacuRest, but it isn't a reason to change an established, working regimen without talking to your ophthalmologist.

What's the difference between this study and the AREDS2 trial?

The AREDS2 trial followed over 4,000 patients for five years and directly measured AMD progression. This new study is a laboratory (in vitro) experiment on donor cells, measuring cellular-level responses rather than patient outcomes. Both are valuable, but they answer different kinds of questions.

Does MacuRest contain the same B-vitamin complex studied here?

MacuRest includes a B-complex alongside the core AREDS2 nutrients, plus 5mg of melatonin that no PreserVision formula includes. It wasn't formulated in response to this specific study, but it reflects the same underlying reasoning about B-vitamin support for AMD-related cellular health.

This article is for informational purposes only and does not constitute medical advice. Patients with AMD should work with a licensed ophthalmologist to determine the right supplement protocol for their specific stage of disease and health history. Last updated July 2026 to reflect preclinical research presented at the AOA's 2026 Optometry's Meeting.